Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)

BACKGROUND: National medical/surgical organizations have recommended the use of neoadjuvant endocrine therapy (NET) to bridge surgery delay of weeks to months for patients with hormone receptor positive (HR+) breast cancer during the ongoing coronavirus disease 2019 (COVID-19) pandemic. The effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldbach, Macy M., Burkbauer, Laura, Bharani, Tina, Williams, Austin D., Keele, Luke, Rothman, Jami, Jankowitz, Rachel, Tchou, Julia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Breast Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202052/
https://www.ncbi.nlm.nih.gov/pubmed/34125350
http://dx.doi.org/10.1245/s10434-021-10287-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202052/
https://www.ncbi.nlm.nih.gov/pubmed/34125350
http://dx.doi.org/10.1245/s10434-021-10287-5

Ejemplares similares